RxDoctor Payments Data

Lisa Dabney, MD

Urogynecology and Reconstructive Pelvic Surgery · New York, NYNPI 1578564266

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Coloplast at 49.3% of the total. Reporting peaked in 2023 at $606 and has fallen 83.2% since, to $102 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in NY, where the typical reported total is $2,552.

$2,048in general payments, 2019–2025

Across 24 payments — averaging $85.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$1K
  • Axonics, Inc.$250
  • Boston Scientific$175
  • Escala Medical Inc.$168
  • Medtronic$145
  • Caldera Medical, Inc$102
  • plus $198 from 4 others

What the payments were for

  • Food & beverage$2,02899%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,048 in reported general payments places this provider in the 40th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.

See all urogynecology and reconstructive pelvic surgery providers in New York

Medicare billing

Part B allowed, 2024
$147,544
Medicare patients
398
Services billed
1,183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron160$82,276
GemtesaVibegron95$56,866
Estradiol375$41,925
PremarinEstrogens, Conjugated46$17,145
YuvafemEstradiol85$10,443
Methenamine Hippurate42$3,102
Clobetasol Propionate15$522
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet12$293
Solifenacin Succinate12$261
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst20$185
Tamsulosin Hcl11$116
Cephalexin15$101
Ibuprofen22$42
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$23

Paid to pharmacies, not to this prescriber.

Other urogynecology and reconstructive pelvic surgery in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →